Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Honigberg, Lee A, Smith, Ashley M, Sirisawad, Mint, Verner, Erik, Loury, David, Chang, Betty, Li, Shyr, Pan, Zhengying, Thamm, Douglas H, Miller, Richard A, Buggy, Joseph J
Published in Proceedings of the National Academy of Sciences - PNAS (20.07.2010)
Published in Proceedings of the National Academy of Sciences - PNAS (20.07.2010)
Get full text
Journal Article
The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia
de Jong, Jan, Sukbuntherng, Juthamas, Skee, Donna, Murphy, Joe, O’Brien, Susan, Byrd, John C., James, Danelle, Hellemans, Peter, Loury, David J., Jiao, Juhui, Chauhan, Vijay, Mannaert, Erik
Published in Cancer chemotherapy and pharmacology (01.05.2015)
Published in Cancer chemotherapy and pharmacology (01.05.2015)
Get full text
Journal Article
Quinazolinone fungal efflux pump inhibitors. Part 3: ( N-methyl)piperazine variants and pharmacokinetic optimization
Watkins, William J., Chong, Lee, Cho, Aesop, Hilgenkamp, Ramona, Ludwikow, Maria, Garizi, Negar, Iqbal, Nadeem, Barnard, John, Singh, Rajeshwar, Madsen, Deidre, Lolans, Karen, Lomovskaya, Olga, Oza, Uma, Kumaraswamy, Padmapriya, Blecken, Andrea, Bai, Shuang, Loury, David J., Griffith, David C., Dudley, Michael N.
Published in Bioorganic & medicinal chemistry letters (15.05.2007)
Published in Bioorganic & medicinal chemistry letters (15.05.2007)
Get full text
Journal Article
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies
Marostica, Eleonora, Sukbuntherng, Juthamas, Loury, David, de Jong, Jan, de Trixhe, Xavier Woot, Vermeulen, An, De Nicolao, Giuseppe, O’Brien, Susan, Byrd, John C., Advani, Ranjana, McGreivy, Jesse, Poggesi, Italo
Published in Cancer chemotherapy and pharmacology (01.01.2015)
Published in Cancer chemotherapy and pharmacology (01.01.2015)
Get full text
Journal Article
BTK USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE BTK
LOURY DAVID J, MODY TARAK D, ELIAS LAURENCE, FYFE GWEN, BUGGY JOSEPH J, HEDRICK ERIC
Year of Publication 20.07.2023
Get full text
Year of Publication 20.07.2023
Patent
Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I
Fouliard, Sylvain, Robert, Renata, Jacquet-Bescond, Anne, du Rieu, Quentin Chalret, Balasubramanian, Sriram, Loury, David, Loriot, Yohann, Hollebecque, Antoine, Kloos, Ioana, Soria, Jean-Charles, Chenel, Marylore, Depil, Stéphane
Published in European journal of cancer (1990) (01.09.2013)
Published in European journal of cancer (1990) (01.09.2013)
Get full text
Journal Article
BTK USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE BTK
LOURY DAVID J, MODY TARAK D, ELIAS LAURENCE, FYFE GWEN, BUGGY JOSEPH J, HEDRICK ERIC
Year of Publication 03.06.2021
Get full text
Year of Publication 03.06.2021
Patent
Use of primary cultures of human hepatocytes in toxicology studies
BUTTERWORTH, B. E, SMITH-OLIVER, T, STROM, S, EARLE, L, LOURY, D. J, WHITE, R. D, DOOLITTLE, D. J, WORKING, P. K, CATTLEY, R. C, JIRTLE, R, MICHALOPOULOS, G
Published in Cancer research (Chicago, Ill.) (01.03.1989)
Get full text
Published in Cancer research (Chicago, Ill.) (01.03.1989)
Journal Article
BTK USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE BTK
LOURY DAVID J, MODY TARAK D, ELIAS LAURENCE, FYFE GWEN, BUGGY JOSEPH J, HEDRICK ERIC
Year of Publication 13.12.2019
Get full text
Year of Publication 13.12.2019
Patent
Abstract 4634: Population pharmacokinetic model of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the treatment of B-cell malignancies
Marostica, Eleonora, Sukbuntherng, Juthamas, Loury, David, Jong, Jan D., Trixhie, Xavier Woot de, Vermeulen, An, Nicolao, Giuseppe de, O'Brien, Susan, Byrd, John C., Advani, Ranjana, McGreivy, Jesse, Poggesi, Italo
Published in Cancer research (Chicago, Ill.) (01.10.2014)
Published in Cancer research (Chicago, Ill.) (01.10.2014)
Get full text
Journal Article
Phase I/II study of PCI-27483, a coagulation factor VIIa (FVIIa) inhibitor, in combination with gemcitabine in patients with advanced pancreatic cancer
Mahesh, Sameer A., Gabrail, Nashat Y., Gandhi, Jitendra G., Khorana, Alok A., Manges, Robert, Shah, Satish, Thomas, Gary W., Hamdy, Ahmed M., Stevens-Brogan, Michelle, Zhou, Cathy, Elias, Laurence, Loury, David, Ramanathan, Ramesh K.
Published in Journal of clinical oncology (20.05.2013)
Published in Journal of clinical oncology (20.05.2013)
Get full text
Journal Article
Abstract A192: PK/PD modeling-based optimization of administration schedule for the histone deacetylase inhibitor (HDACi) S78454/PCI-24781 in phase I
Robert, Renata, Jacquet-Bescond, Anne, Chenel, Marylore, Fouliard, Sylvain, du Rieu, Quentin Chalret, Balasubramanian, Sriram, Loury, David, Loriot, Yohann, Kloos, Ioana, Soria, Jean-Charles, Depil, Stephane
Published in Molecular cancer therapeutics (12.11.2011)
Published in Molecular cancer therapeutics (12.11.2011)
Get full text
Journal Article
The Btk Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity In Patients with Relapsed/Refractory B-Cell Malignancies: Results From a Phase I Study
Fowler, Nathan, Sharman, Jeff Porte, Smith, Sonali M, Boyd, Thomas, Grant, Barbara, Kolibaba, Kathryn S., Furman, Richard R., Buggy, Joseph, Loury, David, Hamdy, Ahmed, Advani, Ranjana
Published in Blood (19.11.2010)
Published in Blood (19.11.2010)
Get full text
Journal Article